FibroGen (FGEN) announced that the China State Administration for Market Regulation approved the sale of FibroGen International to AstraZeneca Treasury (AZN), pursuant to the Share Purchase Agreement, dated February 20. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FibroGen Amends Financing Agreement with Morgan Stanley
- FibroGen’s Strong Financial Position and Promising Clinical Pipeline Drive Buy Rating
- FibroGen’s Hold Rating: Balancing Drug Development Progress and Financial Outlook
- FibroGen’s Strategic Moves and Financial Outlook
- FGEN Upcoming Earnings Report: What to Expect?